Los Angeles, May 2 (IANS) The US Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) have announced the launch of Generation Gold Standard, a next-generation universal vaccine platform designed to combat pandemic-prone viruses.
The platform is based on a beta-propiolactone (BPL)-inactivated, whole-virus approach – a modernised take on traditional vaccine technology, according to the NIH on Thursday.
This initiative represents a decisive shift toward transparency, effectiveness, and comprehensive preparedness, funding the NIH’s in-house development of universal influenza and coronavirus vaccines, including candidates BPL-1357 and BPL-24910, said the NIH in a statement.
These vaccines aim to provide broad-spectrum protection against multiple strains of pandemic-prone viruses such as H5N1 avian influenza and coronaviruses including SARS-CoV-2, SARS-CoV-1, and MERS-CoV, according to the NIH.
“Our commitment is clear: every innovation in vaccine development must be grounded in gold standard science and transparency, and subjected to the highest standards of safety and efficacy testing,” said HHS Secretary Robert F. Kennedy, Jr.
The program realigns Biomedical Advanced Research and Development Authority’s (BARDA) operations with its statutory mission under the Public Health Service Act — to prepare for all influenza viral threats, not just those currently circulating, Xinhua news agency reported.
The move comes amid mass cuts at the agency, such as terminated NIH research grants and a workforce reduction designed to impact nearly 20,000 HHS staffers.
A document leaked last month revealed unofficial plans from President Donald Trump’s administration to slash the NIH’s budget by about 40 per cent, from $47 billion to $27 billion.
The new project’s funds will come from the BARDA, an HHS centre designed to finance medical countermeasures against public health threats.
The initiative seeks to replace the Biden’s administration’s Project NextGen, a $5 billion effort to accelerate next-gen Covid-19 countermeasures to address waning immunity and resistance.
In a statement, the HHS spokesperson said the Biden-era program was “wasteful” and “neglecting broader pandemic preparedness”.
“Generation Gold Standard is a paradigm shift,” said NIH Director Jay Bhattacharya.
“It extends vaccine protection beyond strain-specific limits and prepares for flu viral threats — not just today’s, but tomorrow’s as well — using traditional vaccine technology brought into the 21st century.”
Clinical trials for universal influenza vaccines are scheduled to begin in 2026, with the US Food and Drug Administration approval targeted for 2029, according to the NIH.
–IANS
int/khz
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
